TY - JOUR
T1 - Human growth hormone stabilizes walking and improves strength in a patient with dominantly inherited calpainopathy
AU - Prahm, Kira Philipsen
AU - Feldt-Rasmussen, Ulla
AU - Vissing, John
N1 - Copyright © 2017 Elsevier B.V. All rights reserved.
PY - 2017/4/1
Y1 - 2017/4/1
N2 - The aim was to investigate if daily low-dose treatment with recombinant human growth hormone (somatropine) can stabilize or improve muscle strength and walking capability in a patient with dominantly inherited calpainopathy. The patient was treated with daily injections of somatropine, except for a 6-month pause, over a period of 4.5 years. Efficacy was assessed by repeated muscle dynamometry tests and 6-minute walk tests (6MWT). Strength improved in most muscle groups on treatment, deteriorated in the 6-month off treatment, and improved again when treatment was resumed. The 6MWT stabilized during the initial 18-month treatment period, then deteriorated in the 6 months off treatment and improved to pre-trial levels when treatment was resumed. The findings suggest that supplementation with somatropine, within physiological ranges, may improve muscle strength and stabilize walking capability in a patient with calpainopathy. This finding calls for testing of somatropine supplementation in muscular dystrophies in a randomized study.
AB - The aim was to investigate if daily low-dose treatment with recombinant human growth hormone (somatropine) can stabilize or improve muscle strength and walking capability in a patient with dominantly inherited calpainopathy. The patient was treated with daily injections of somatropine, except for a 6-month pause, over a period of 4.5 years. Efficacy was assessed by repeated muscle dynamometry tests and 6-minute walk tests (6MWT). Strength improved in most muscle groups on treatment, deteriorated in the 6-month off treatment, and improved again when treatment was resumed. The 6MWT stabilized during the initial 18-month treatment period, then deteriorated in the 6 months off treatment and improved to pre-trial levels when treatment was resumed. The findings suggest that supplementation with somatropine, within physiological ranges, may improve muscle strength and stabilize walking capability in a patient with calpainopathy. This finding calls for testing of somatropine supplementation in muscular dystrophies in a randomized study.
KW - Aged
KW - Female
KW - Human Growth Hormone/pharmacology
KW - Humans
KW - Muscle Strength/drug effects
KW - Muscular Dystrophies, Limb-Girdle/drug therapy
U2 - 10.1016/j.nmd.2017.01.015
DO - 10.1016/j.nmd.2017.01.015
M3 - Journal article
C2 - 28190647
SN - 0960-8966
VL - 27
SP - 358
EP - 362
JO - Journal of Neuromuscular Diseases
JF - Journal of Neuromuscular Diseases
IS - 4
ER -